Menu

2013

RedHill Biopharma Announces Positive FDA Meeting Regarding the Regulatory Path towards NDA Submission of RHB-101

29 May, 2013 RedHill Biopharma Announces Positive FDA Meeting Regarding the Regulatory Path towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension

RedHill Biopharma Receives Positive Feedback From a Scientific Advice Meeting in Europe

19 March, 2013 RedHill Biopharma Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan

RedHill announces new patent and provides update on RHB-104 (Crohn's)

7 January, 2013